Connect with us

Press Releases

Aurion Biotech Appoints Professor Shigeru Kinoshita, MD, PhD, to Its Medical Advisory Board

Leading ophthalmology researcher, surgeon and inventor of corneal endothelial cell therapy will support the product’s clinical development.

mm

Published

on

Aurion Biotech Appoints Professor Shigeru Kinoshita, MD, PhD, to Its Medical Advisory Board

Professor Shigeru Kinoshita, Kyoto Prefecture University of Medicine (Photo: Business Wire)

(PRESS RELEASE) SEATTLE, BOSTON AND TOKYO — Shigeru Kinoshita, MD, PhD, has joined the medical advisory board at Aurion Biotech, whose mission is to cure blindness by developing a differentiated platform of advanced therapies to treat ocular diseases. Professor Kinoshita is the inventor of Aurion Biotech’s lead candidate, cell therapy for the treatment of corneal endothelial disease. As a member of the company’s medical advisory board, he will continue to support the product’s clinical development.

“We are honored that Professor Kinoshita has agreed to join our medical advisory board,” said Greg Kunst, chief executive officer of Aurion Biotech. “His many distinguished accomplishments, his generosity with students and colleagues, and his exciting discoveries have profoundly transformed the treatment landscape for ophthalmology. We look forward to his insights and guidance in the months and years ahead.”

In 1992, Professor Shigeru Kinoshita, MD, PhD, was appointed professor and chair of the department of ophthalmology at Kyoto Prefecture University of Medicine (KPUM). Since 2015, he has held the title of professor and chair in the department of frontier medical science and technology for ophthalmology at KPUM.

“I am pleased to join the Aurion Biotech medical advisory board,” said Professor Kinoshita. “We share a common objective: to advance the development of corneal endothelial cell therapy, in order to bring this procedure to millions of patients who suffer from corneal blindness. I look forward to our continued productive collaboration.”

Previously, while at Harvard University’s Schepens Eye Research Institute, Professor Kinoshita – in collaboration with Dr. Richard A. Thoft – established the concept of centripetal movement of the corneal epithelium. This groundbreaking work shed new light on the importance of the limbal epithelium. Professor Kinoshita’s discoveries have had an enormous impact on this subject, ultimately contributing to the development of corneal endothelial cell therapy, which is now being further developed by Aurion Biotech.

Advertisement

“I’ve had the pleasure of knowing Shigeru Kinoshita for many years,” said Edward Holland, MD, Aurion Biotech chief medical advisor and chair of its medical advisory board. “He has devoted his entire career to research, innovation, surgery, teaching and mentorship in ophthalmology. His insights and expertise in corneal endothelial cell therapy will be invaluable to us, as together we work to bring this procedure to patients in need.”

Professor Kinoshita is internationally recognized and holds multiple awards and appointments. He is a recipient of the Alcon Research Institute Award, the Castroviejo Medal Lecturer of the Cornea Society and the Friedenwald Award Lecturer of ARVO. He served as an ARVO program committee member between 1996 and 1999, and ARVO trustee between 2006 and 2011 in the cornea section, and was the vice president of ARVO in 2011. Professor Kinoshita also served as associate editor of Investigative Ophthalmology & Visual Science. Professor Kinoshita received his medical degree from Osaka University Medical School.

SPONSORED VIDEO

SPONSORED BY VARILUX

The Best Overall Progressive Lens, Now Powered by AI

Engineered with Behavioral Artificial Intelligence and utilizing new XR-motion™ technology, Varilux XR series goes beyond prescription and eye physiology to consider the patient’s visual behavior and design a progressive lens that respects how
their eyes naturally move.

Varilux XR series comes in two versions, Varilux® XR design and Varilux® XR track. The Varilux XR track lens provides an additional level of personalization by incorporating the exclusive Near Vision Behavior Measurement, providing up to 25% more near vision width3 according to the patient’s need, so patients get the highest level of customization.

Discover Varilux XR series and enjoy instantly sharp vision in motion4 and seamless transitions from near to far.

For more information, visit here.

Promoted Headlines

Advertisement

Advertisement

Advertisement

Subscribe

INVISIONMAG.COM
BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Instagram

Most Popular